- Home
- INVA vs NVAX Comparison
INVA vs NVAX Comparison
Compare INVA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | NVAX |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INVA | NVAX |
|---|---|---|
| Price | $22.39 | $10.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | ★ $36.50 | $11.33 |
| AVG Volume (30 Days) | 730.3K | ★ 4.3M |
| Earning Date | 05-28-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | 309.76 |
| EPS | ★ 3.30 | 2.58 |
| Revenue | $217,217,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $11.99 | N/A |
| P/E Ratio | $6.68 | ★ $3.85 |
| Revenue Growth | 62.63 | ★ 64.69 |
| 52 Week Low | $16.52 | $5.01 |
| 52 Week High | $25.15 | $11.85 |
Technical Indicators
Market Signals| Indicator | INVA | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 62.16 |
| Support Level | $19.16 | $6.34 |
| Resistance Level | $22.76 | $11.85 |
| Average True Range (ATR) | 0.71 | 0.72 |
| MACD | -0.23 | 0.05 |
| Stochastic Oscillator | 18.46 | 62.35 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.